Market Overview

UPDATE: Credit Suisse Lowers PT on Arena Pharmaceuticals Following Management Meeting

Related ARNA
Wednesday's Mid-Day Movers: Does The U.S. Benefit From Iran Deal?; Celgene-Receptos And More
Mid-Morning Market Update: Markets Mostly Higher; Bank Of America Tops Q2 Views
Arena - A Deeper Look At APD-334 (Seeking Alpha)

In a report published Monday, Credit Suisse analyst Lee Kalowski reiterated an Underperform rating on Arena Pharmaceuticals (NASDAQ: ARNA), but lowered the price target from $5.00 to $4.00.

In the report, Credit Suisse noted, “As Q3 closes and following a Friday meeting with management, we are lowering our Belviq US net sales estimate for Q3, Q4, and each year through 2018 (2019-2020 are unchanged). We expect consensus will be coming down in the weeks ahead. We think a capital raise may potentially be required next year and have built this into our model. With these changes, our DCF-derived target price goes from $5 to $4.”

Arena Pharmaceuticals closed on Friday at $5.79.

Latest Ratings for ARNA

Nov 2013WallachbethInitiates Coverage onBuy
Oct 2013Cowen & CompanyInitiates Coverage onMarket Perform
Oct 2013Piper JaffrayMaintainsOverweight

View More Analyst Ratings for ARNA
View the Latest Analyst Ratings

Posted-In: Credit Suisse Lee KalowskiAnalyst Color Price Target Analyst Ratings


Related Articles (ARNA)

View Comments and Join the Discussion!

Get Benzinga's Newsletters